Programme – No Smoke Summit 2019

Wednesday 29/5/2019
Thursday 30/5/2019

8:00-9:00	Registrations
9:00-9:30	Opening remarks
9:30-11:00	Epidemiology & Prevention of Smoking: Where do we stand? Chairs: Demetrios Kouretas & Mina Gaga – The Global Burden of Tobacco: The emerging scenery, Adamantia Liapikou – Epidemiological data from e-cigarette in Greece, Anastasia Barbouni – Prevention of smoking in adolescents: helped or hindered by e-cigarettes?, Lion Shahab
11:00-11:30	Coffee Break
11:30-13:00	Tobacco Control – Smoking Cessation Chairs: Elias Tsougos & Paraskevi Katsaounou – Organization and operation of a smoking cessation clinic, Kallirrhoe Kourea – Smoking Cessation in cardiovascular patients, Georgios Goumas – Smoking Cessation in respiratory patients, Zafeiria Barbaressou – Should octagenarians quit smoking?, Vassiliki Giannakopoulou


13:00-13:30	Keynote Lecture: Nicotine vs. smoke: key differences in effects and risks, Jacques Le Houezec Chair: Ignatios Ikonomidis
13:30-14:30	Lunch Break \|\| Poster Presentation & Discussion
14:30-16:30	Tobacco Control – Harm Reduction & Public Health Tobacco Harm Reduction and Tobacco Control: complementary or contradictory? Chairs: Konstantinos Farsalinos & Michael Toumbis – Harm reduction in smoking. Wolf in sheep’s clothing, Paraskevi Katsaounou – The Changing Global Picture of Tobacco Harm Reduction, Karl Fagerström – The case of snus, Lars Ramstrom – Harm reduction in Iceland, Karl Snæbjörnsson Panel Discussion: Why is Tobacco Harm Reduction so Divisive? Panelists: Martin Dockrell, Lion Shahab



16:30-17:00	Coffee Break
17:00-19.00	Regulation and Public Health & Policy Chairs: Konstantinos Poulas & Anastasia Barbouni – Implementation of Harm Reduction Policies in Public Health, Kostas Athanasakis – How to evaluate the alternative Tobacco Products – FDA’s Regulatory Approach, Michael Toumbis – A Tobacco Control Plan for England – Challenges and Achievements, Martin Dockrell – The case in Greece: Considerations & Opportunities, Dimitri Richter Panel Discussion: Main Priorities of Public Health and how to integrate innovative and traditional health policies into an effective Tobacco Control Plan Panelists: Solomon Rataemane, Karl Snæbjörnsson, Karl Fagerström, Sudhanshu Patwardhan, and Konstantinos Farsalinos

9:00-11.00	Science – Research – Evidence (PART I) Chair: Stavros Topouzis *Epidemiology & Social Issues (Perception risk, Attractiveness etc.)* • Electronic cigarette use among adolescents in Greece: A cross-sectional school study in the Metropolitan area of Athens,Nadia Maglara • Patterns of use, past smoking status and biochemically verified current smoking status of heated tobacco product (IQOS) shops customers: preliminary results, Efthymia Panagiotopoulou *Toxicology and aerosol chemistry – Chemical composition of the aerosol, droplet size and distribution, temperature and toxicants, indoor air quality* • Aldehyde content in the vapour produced by Glo, Nikolaos Vlachos *Biomarkers’ evaluation in animal or human studies* • Electronic cigarette smoking increases arterial stiffness and oxidative stress to a lesser extent than a single conventional cigarette: an acute and a chronic study, Dimitrios Vlastos • Electronic cigarette smoking causes less impairment of platelet function and oxidative stress than tobacco cigarette smoking, Gavriella Kostelli *Preclinical evaluation* • The in vitro assessment of a tobacco heating product (GLO), Damien Breheny • A six-month systems toxicology inhalation/cessation study in ApoE^-/- mice to investigate cardiovascular and respiratory exposure effects of a potential candidate and a candidate modified risk tobacco product, CHTP 1.2 and THS 2.2 respectively, compared with cigarettes, Bjoern Titz • Chronic Toxicity and Lung Tumorigenesis in A/J mice following lifetime exposure to aerosol from the Tobacco Heating System (THS) 2.2 in comparison to exposure to 3R4F reference cigarette smoke, Bjoern Titz

11:00-11:30	Coffee Break
11:30-13:30	Science – Research – Evidence (PART II) Chairs: Demetrios Kouretas & Ignatios Ikonomidis *Smoking cessation* • Effects of Varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program, Margarita Marinou • E-cigarette use and biochemically confirmed smoking status of a random sample of vapeshops customers in Greece, Eleni Diamantopoulou • Role of healthcare practitioners in enabling and accelerating smoking cessation among their smoker patients- a UK perspective, Sudhanshu Patwardhan • Association of flavored nicotine salt pod system use and subsequent switching behavior, Carrie M. Carretta, Jeff Vaughan, and Will Mullen • Transitions in adults’ cigarette smoking status associated with using JUUL vaping products for three months, Christopher Russell *Clinical Assessment and Harm Reduction* • Tobacco heating system vs. combustible cigarettes: can lung function parameters be improved?, Francesco Sergio • Smoking cessation & novel smoking products, Ignatios Ikonomidis



13:30-14:30	Lunch Break
14:30-16:00	Panel Discussion: Clinical practice experience on Smoking Cessation Chairs: Michael Toumbis Panelists: Angeliki Florou, Kallirrhoe Kourea, Sudhanshu Patwardhan, and Vassiliki Doumou


16:00-16:30	Coffee Break
16:30-17:00	Keynote Lecture: The dilemma of smoking addiction in psychiatric patients, Solomon Rataemane Chair: Anastasia Barbouni
17:00-18:00	Panel Discussion – Bioethics: Key considerations and how to maximize benefits for smokers and minimize potential harms for youth Chair: Tina Garani-Papadatos Panelists: Lion Shahab, Nikos Dedes, Emilios Negis, Christopher Russell, and Manolis Souvatzis
18:00-18:30	Closing Remarks Organising Committee